US demand for pharmaceutical excipients is expected to approach $2 billion in 2015, driven by growing production of pharmaceuticals in the US and the increasing importance of improved excipients in drug formulations. Pharmaceutical companies are emphasizing the use and development of new and/or improved inactive ingredients in response to the growing problems of patent expirations for key products, increasing competition from foreign suppliers and downward pricing pressure from end users. Of particular interest to pharmaceutical companies is the development of new, patentable proprietary formulations that can be used to compete with generic products. Excipients can be used to provide more convenient dosage formats and are important to maintaining the efficacy, stability, safety and longevity of medicines.
Pharmaceutical companies are increasingly interested in developing new, patentable proprietary drugs that can be used to compete with generic formulations. Once only fillers and conduits for active ingredients, excipients are now used to provide more convenient dosage forms, to deliver drugs effectively, to control the timing of release (delayed, immediate), and to provide immediate disintegration in special circumstances. Their importance in drug delivery, safety, stability, efficacy and convenience can be crucial to patient compliance. Growth opportunities will extend to a wide range of compounds and applications. Cellulosic materials will remain the dominant materials for excipient fillers, but will expand sales through specialty combination of excipients to improve and reduce the costs of tableting. Gelatin will remain the leading compound for encapsulation based on continued solid performance and safety, withstanding challenges from more expensive cellulosic and vegetable oil derivative alternatives, but will be used increasingly to encapsulate granules of active ingredients and to improve coatings. Lactose, used most often as a filler, is now being developed as an inhalant for drug delivery. Other products are under development that can deliver active ingredients to specific places in the body, or improve the release of newly developed medicines that do not break down in water.
Excipient producers are marketing combination materials that, together, improve overall performance in producing finished tablets of higher quality at reduced cost. Cellulosic excipients will experience significant growth through 2015 due to the development of co-processed materials that combine properties of compressibility and flowability. Composites of microcrystalline cellulose (MCC), hydroxypropyl methylcellulose (HPMC) and Corpovidone (CPVD) are engineered for binding, filling and disintegrating capabilities that exceed the quality of action in individual excipients, and ensure product consistency. MCC will see particularly strong growth because of its capacity for use in direct compression in tableting -- a process that is substantially less expensive than the more standard wet granulation process for the same purpose. Multifunctional synthetic polymers such as polyethylene glycol (PEG) and povidone will continue to experience strong growth because of their broad application for high value-added oral medicines, including their use for controlled release and disintegration.
This new Freedonia US industry study, “Excipients”, presents historical demand data (2000, 2005 and 2010) plus forecasts for 2015 and 2020 by excipient product and application. The study also considers key market environment factors, assesses industry structure, evaluates company market share and profiles 60 industry competitors.